Venetoclax, Ponatinib, and Dexamethasone in Participants With Philadelphia Chromosome or BCR-ABL Positive Relapsed or Refractory Acute Lymphoblastic Leukemia or Chronic Myelogenous Leukemia

Clinical trial NCT03576547 · TERMINATED

Trial details

NCT number: NCT03576547
Sponsor: M.D. Anderson Cancer Center
Status: TERMINATED
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive Philadelphia Chromosome Positive Recurrent Acute Lymphoblastic Leukemia Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive Refractory Acute Lymphoblastic Leukemia Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive t(9;22)

Start date: 2018-06-26
Primary completion: 2024-06-19
Enrollment: 9

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.